Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab plus tislelizumab versus pembrolizumab in first-line PD-L1-high advanced non-small cell lung cancer
CTR20211476Phase 3Terminated
- Sponsor
- BeiGene
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ociperlimab, tislelizumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Jul 2021; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211476.